Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
927.15
-19.95 (-2.11%) Zydus Lifesciences informs about press release
Date: 11-07-2022Zydus Lifesciences has informed that it enclosed a copy of press release dated July 11, 2022 titled ‘Zydus receives final approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets’.
The above information is a part of company’s filings submitted to BSE.